| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24e76490bed88751680a5fef9bc73892 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G06F19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2005-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1ea5ebfdccc40008e72b5b5085a8c0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75ace5601de96c538f9d33b3214ee100
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7dc63c3842b29454a50e6a2e6f499ef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a387efc401305898036bbbcfb030ad7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_612e666d59632e47f82f1c98711fa232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f87c7f720d4a59975613874c4b439995
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33aa401f736c46fb0acd0f3329a4c5ea |
| publicationDate |
2006-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006134671-A1 |
| titleOfInvention |
Methods and systems for prognosis and treatment of solid tumors |
| abstract |
The present invention provides methods, systems and equipment for the prognosis and treatment of renal cell carcinoma (RCC) or other solid tumors. Genes prognostic of clinical outcomes of a solid tumor can be identified according to the present invention. The expression profiles of these genes in peripheral blood mononuclear cells (PBMCs) of patients who have the solid tumor are correlated with clinical outcome of these patients. Examples of RCC prognosis genes are illustrated in Tables 2 and 3. These genes can be used as surrogate markers for predicting clinical outcome of an RCC patient of interest. These genes can also be used for the selection of a favorable treatment for an RCC patient of interest. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8756190-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017109439-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011066586-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009030884-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009030884-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008032299-A1 |
| priorityDate |
2004-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |